文献速递淋巴瘤

资源受限环境下影像学检查方式对霍奇金淋巴瘤临床结局的影响

Impact of imaging modality on clinical outcome in Hodgkin lymphoma in a resource constraint setting.
PubMed 文献 · Br J Haematol · 2019-12-07

该研究回顾性分析了283例霍奇金淋巴瘤患者,其中268例完成6周期ABVD化疗后分别采用CT/PET或临床检查/超声/X线评估疗效。结果显示两组无复发生存率无显著差异,提示在资源受限时可使用基础影像模态。

要点

  • 资源受限时可用临床检查、超声和X线替代CT/PET评估霍奇金淋巴瘤化疗后疗效。
  • 基础影像组与CT/PET组的3年无复发生存率无显著差异。
  • 晚期疾病是唯一显著影响无复发生存的不良因素。

核心结论

  • 在资源受限环境下,使用临床检查、腹部超声和/或X线评估霍奇金淋巴瘤化疗后疗效,其复发率与使用CT或PET-CT评估无显著差异。

研究设计与样本

  • 回顾性研究,纳入2011至2015年治疗的283例霍奇金淋巴瘤患者,其中268例完成6周期ABVD化疗。
  • 185例采用CT/PET评估,83例采用临床检查/超声/X线评估。

临床怎么用

  • 在资源受限情况下,可采用临床检查、腹部超声和/或X线作为霍奇金淋巴瘤化疗后疗效评估的替代方式,结局可接受。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment of Hodgkin lymphoma (HL) has evolved with risk-stratified therapy based on PET-CT scan at multiple timepoints. In a resource constraint setting even a single PET-CT scan ($400) is inaccessible to many patients, who are re-assessed with only clinical examination, abdominal ultrasonogram and/or x-ray (C/U/X) ($10). To compare clinical outcomes in patients with HL who have had suboptimal imaging after completion of chemotherapy for HL, with those who had a CT or PET-CT, 283 patients were treated for HL from 2011 to 2015, and 268 patients completed six cycles of ABVD therapy with response assessment modality by CT/PET in 185 patients and by C/U/X in 83. There was no difference in the number of patients with advanced (64·1% vs. 61·1%; P = 0·650) or bulk disease (8·1% vs. 7·2%). A significantly higher number of patients in the CT/PET group received IFRT (25·4% vs. 7·7%; P = 0·0005). The three-year overall survival and progression-free survival of all treated patients (n = 283) was 83·5 ± 2·3% and 76·7 ± 2·6% respectively [median follow-up 36 months (range 2-93)]. At three years, the overall relapse-free survival (RFS) was 80·1 ± 2·5%, with RFS of 77 ± 3·2% vs. 85 ± 4·0% in the CT/PET group and C/U/X groups respectively (P = 0·349). There was no difference in RFS between the two groups either in early-stage disease (88·1 ± 4·6% vs. 91·8 ± 5·6%; P = 0·671) or late-stage disease (73·9 ± 4·8% vs. 81·3 ± 6·0%; P = 0·747). The only significant factor adversely affecting RFS was advanced disease (P = 0·004). Factors not affecting RFS were age (P = 0·763), sex (P = 0·925), bulk disease (P = 0·889) and imaging modality (P = 0·352). There was no difference in relapse rates between patients who had suboptimal imaging compared to those who had a PET/CT. It is possible to use these basic imaging modalities when resources are a constraint, with acceptable outcomes.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Korula A, Devasia AJ, Kulkarni U, et al. Impact of imaging modality on clinical outcome in Hodgkin lymphoma in a resource constraint setting. Br J Haematol. 2019. PMID: 31811734. doi:10.1111/bjh.16289

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。